将[177Lu]Lu-DOTA-TOC肽受体放射性核素治疗与PARP抑制剂联合以增强小细胞肺癌疗效
本研究在小细胞肺癌(SCLC)细胞系与异种移植模型中评估PARP抑制剂(Olaparib、Rucaparib)联合[177Lu]Lu-DOTA-TOC肽受体放射性核素治疗(PRRT)的效果。体外联合治疗较单药[177Lu]Lu-DOTA-TOC效力提高2.9至67倍,体内联合治疗使肿瘤倍增时间增加至1.6倍(H446)和2.2倍(H69),中位生存期高于单药及未治疗组。作者认为基于结果值得在人体中进一步评估。
要点
- H446与H69细胞SSTR2配体摄取较AR42J细胞低60%至90%。
- 体外[177Lu]Lu-DOTA-TOC联合PARP抑制剂效力较单药提高2.9至67倍。
- 体内联合治疗使肿瘤倍增时间增加至1.6倍(H446)和2.2倍(H69)。
核心结论
- 添加PARP抑制剂可显著提高SSTR2靶向PRRT在SSTR2低表达SCLC模型中的效力。
- 基于该结果,作者认为值得在人体中进一步评估,因为SCLC亟需新的治疗选择。
研究设计与样本
- 体外使用SCLC细胞系H69和H446评估SSTR2配体摄取(流式细胞术)及单药与联合治疗反应(细胞活力、克隆形成存活、γH2AX DNA损伤检测)。
- 体内使用荷H69或H446异种移植瘤的裸鼠,给予Olaparib、Rucaparib或[177Lu]Lu-DOTA-TOC单药或联合方案,评估肿瘤生长与生存。
- 体内另评估了PRRT剂量分次给药对治疗效果的影响。
主要发现
- H446和H69细胞SSTR2表达低,SSTR2配体摄取较AR42J细胞低60%至90%。
- 体外[177Lu]Lu-DOTA-TOC联合PARP抑制剂效力较单药[177Lu]Lu-DOTA-TOC提高2.9至67倍。
- 联合治疗较单药克隆形成存活降低、持续性DNA损伤增加(Olaparib和Rucaparib均如此)。
- 体内联合治疗肿瘤倍增时间增加至1.6倍(H446)和2.2倍(H69),单药治疗为1.0至1.1倍(H446)和1.1至1.7倍(H69)(均与未治疗动物相比)。
- 两个模型中联合治疗组中位生存期均高于单药组和未治疗组;PRRT剂量分次给药未进一步改善治疗结局。
局限性
- 原文结论指出基于结果值得在人体中进一步评估,表明当前证据限于临床前模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive tumor with neuroendocrine origin. Although SCLC frequently express somatostatin receptor type 2 (SSTR2), a significant clinical benefit of SSTR2-targeted radionuclide therapies of SCLC was not observed so far. We hypothesize that combination treatment with a PARP inhibitor (PARPi) could lead to radiosensitization and increase the effectiveness of SSTR2-targeted therapy in SCLC. METHODS: SSTR2-ligand uptake of the SCLC cell lines H69 and H446 was evaluated in vitro using flow cytometry, and in vivo using SPECT imaging and cut-and-count biodistribution. Single-agent (Olaparib, Rucaparib, [177Lu]Lu-DOTA-TOC) and combination treatment responses were determined in vitro via cell viability, clonogenic survival and γH2AX DNA damage assays. In vivo, we treated athymic nude mice bearing H69 or H446 xenografts with Olaparib, Rucaparib, or [177Lu]Lu-DOTA-TOC alone or with combination treatment regimens to assess the impact on tumor growth and survival of the treated mice. RESULTS: H446 and H69 cells exhibited low SSTR2 expression, i.e. 60 to 90% lower uptake of SSTR2-ligands compared to AR42J cells. In vitro, combination treatment of [177Lu]Lu-DOTA-TOC with PARPi resulted in 2.9- to 67-fold increased potency relative to [177Lu]Lu-DOTA-TOC alone. We observed decreased clonogenic survival and higher amounts of persistent DNA damage compared to single-agent treatment for both Olaparib and Rucaparib. In vivo, tumor doubling times increased to 1.6-fold (H446) and 2.2-fold (H69) under combination treatment, and 1.0 to 1.1-fold (H446) and 1.1 to 1.7-fold (H69) in monotherapies compared to untreated animals. Concurrently, median survival was higher in the combination treatment groups in both models compared to monotherapy and untreated mice. Fractionating the PRRT dose did not lead to further improvement of therapeutic outcome. CONCLUSION: The addition of PARPi can markedly improve the potency of SSTR2-targeted PRRT in SCLC models in SSTR2 low-expressing tumors. Further evaluation in humans seems justified based on the results as novel treatment options for SCLC are urgently needed.
引用
- Rauch H, Kitzberger C, Janghu K, et al. Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39023784. doi:10.1007/s00259-024-06844-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。